The Human Pathology Atlas for Deciphering the Prognostic Features of Human Cancers

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2024 Dec 11

PMID 39662180

Authors

Meng Yuan

Cheng Zhang

Kalle Von Feilitzen

Martin Zwahlen

Mengnan Shi

Xiangyu Li

Hong Yang

Xiya Song

Hasan Turkez

Mathias Uhlen

Adil Mardinoglu

Affiliations

Soon will be listed here.

Abstract

Background: Cancer is one of the leading causes of mortality worldwide, highlighting the urgent need for a deeper molecular understanding and the development of personalized treatments. The present study aims to establish a solid association between gene expression and patient survival outcomes to enhance the utility of the Human Pathology Atlas for cancer research.

Methods: In this updated analysis, we examined the expression profiles of 6918 patients across 21 cancer types. We integrated data from 10 independent cancer cohorts, creating a cross-validated, reliable collection of prognostic genes. We applied systems biology approach to identify the association between gene expression profiles and patient survival outcomes. We further constructed prognostic regulatory networks for kidney renal clear cell carcinoma (KIRC) and liver hepatocellular carcinoma (LIHC), which elucidate the molecular underpinnings associated with patient survival in these cancers.

Findings: We observed that gene expression during the transition from normal to tumorous tissue exhibited diverse shifting patterns in their original tissue locations. Significant correlations between gene expression and patient survival outcomes were identified in KIRC and LIHC among the major cancer types. Additionally, the prognostic regulatory network established for these two cancers showed the indicative capabilities of the Human Pathology Atlas and provides actionable insights for cancer research.

Interpretation: The updated Human Pathology Atlas provides a significant foundation for precision oncology and the formulation of personalized treatment strategies. These findings deepen our understanding of cancer biology and have the potential to advance targeted therapeutic approaches in clinical practice.

Funding: The Knut and Alice Wallenberg Foundation (72110), the China Scholarship Council (Grant No. 202006940003).

References

Frick C, Rumgay H, Vignat J, Ginsburg O, Nolte E, Bray F . Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: a population-based study. Lancet Glob Health. 2023; 11(11):e1700-e1712. PMC: 10581909. DOI: 10.1016/S2214-109X(23)00406-0. View

Menyhart O, Gyorffy B . Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J. 2021; 19:949-960. PMC: 7868685. DOI: 10.1016/j.csbj.2021.01.009. View

Chong Y, Toh T, Chan Z, Xuan Lin Q, Thng D, Hooi L . Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression. Hepatol Commun. 2020; 4(9):1362-1381. PMC: 7471427. DOI: 10.1002/hep4.1559. View

Margolin A, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R . ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics. 2006; 7 Suppl 1:S7. PMC: 1810318. DOI: 10.1186/1471-2105-7-S1-S7. View

Propper D, Balkwill F . Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022; 19(4):237-253. DOI: 10.1038/s41571-021-00588-9. View

Li X, Shong K, Kim W, Yuan M, Yang H, Sato Y . Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach. EBioMedicine. 2022; 78:103963. PMC: 8960981. DOI: 10.1016/j.ebiom.2022.103963. View

Gandaglia G, Becker A, Trinh Q, Abdollah F, Schiffmann J, Roghmann F . Long-term survival in patients with germ cell testicular cancer: a population-based competing-risks regression analysis. Eur J Surg Oncol. 2013; 40(1):103-12. DOI: 10.1016/j.ejso.2013.09.019. View

Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K . KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2016; 45(D1):D353-D361. PMC: 5210567. DOI: 10.1093/nar/gkw1092. View

Yang Y, Hong P, Xu W, He Q, Li B . Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 2020; 5(1):229. PMC: 7542465. DOI: 10.1038/s41392-020-00323-3. View

10.

Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T . Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013; 45(8):860-7. DOI: 10.1038/ng.2699. View

11.

Xu T, Ruan H, Gao S, Liu J, Liu Y, Song Z . ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma. Aging (Albany NY). 2020; 12(2):1808-1827. PMC: 7053611. DOI: 10.18632/aging.102714. View

12.

Takakura S, Kohno T, Manda R, Okamoto A, Tanaka T, Yokota J . Genetic alterations and expression of the protein phosphatase 1 genes in human cancers. Int J Oncol. 2001; 18(4):817-24. DOI: 10.3892/ijo.18.4.817. View

13.

Nehme Z, Roehlen N, Dhawan P, Baumert T . Tight Junction Protein Signaling and Cancer Biology. Cells. 2023; 12(2). PMC: 9857217. DOI: 10.3390/cells12020243. View

14.

Quinlan A, Hall I . BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010; 26(6):841-2. PMC: 2832824. DOI: 10.1093/bioinformatics/btq033. View

15.

Miao D, Margolis C, Gao W, Voss M, Li W, Martini D . Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018; 359(6377):801-806. PMC: 6035749. DOI: 10.1126/science.aan5951. View

16.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

17.

Goldmann T, Marwitz S, Nitschkowski D, Krupar R, Backman M, Elfving H . PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung. Cancer Immunol Immunother. 2021; 70(9):2577-2587. PMC: 8360842. DOI: 10.1007/s00262-020-02825-z. View

18.

Elgohary N, Pellegrino R, Neumann O, Elzawahry H, Saber M, Zeeneldin A . Protumorigenic role of Timeless in hepatocellular carcinoma. Int J Oncol. 2014; 46(2):597-606. DOI: 10.3892/ijo.2014.2751. View

19.

Gao M, Lin Y, Liu X, Li Y, Zhang C, Wang Z . ISG20 promotes local tumor immunity and contributes to poor survival in human glioma. Oncoimmunology. 2019; 8(2):e1534038. PMC: 6343791. DOI: 10.1080/2162402X.2018.1534038. View

20.

Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View